Harsco Corporation (HSC)
Price:
9.15 USD
( + 0.21 USD)
Your position:
0 USD
ACTION PANEL
ABOUT
Check the
KEY TAKEAWAYS
ASK OUR AI ABOUT THE COMPANY (REGISTER FOR EARLY ACCESS)

(REGISTER FOR EARLY ACCESS) CHOOSE A PROMPT ABOVE TO ASK OUR AI ABOUT THE SPECIFIC INFORMATION
SIMILAR COMPANIES STI SCORE
Similar STI Score
Li-Cycle Holdings Corp.
VALUE SCORE:
0
2nd position
Republic Services, Inc.
VALUE SCORE:
8
The best
GFL Environmental Inc.
VALUE SCORE:
9
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS
FUNDAMENTALS PER SHARE
TECHNICAL
DIVIDEND
SIMILAR COMPANIES
DESCRIPTION
Harsco Corporation provides environmental solutions for industrial and specialty waste streams worldwide. It operates through two segments, Harsco Environmental and Harsco Clean Earth. The Harsco Environmental segment offers on-site services for material logistics, product quality improvement, and resource recovery for iron, steel, and metals manufacturing; manufactures and sells industrial abrasives, roofing granules, aluminum dross, and scrap processing systems; and produces value-added downstream products from industrial waste-stream. The Harsco Clean Earth segment provides waste management services, including transportation, specialty waste processing, and recycling and beneficial reuse solutions for hazardous wastes, and soil and dredged materials. The company was founded in 1853 and is headquartered in Camp Hill, Pennsylvania.
NEWS

Harsco Environmental Expands Presence in Central Europe With Two New Contracts in Slovakia
globenewswire.com
2025-09-18 08:00:00LONDON, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Harsco Environmental, a division of Enviri Corporation (NYSE: NVRI), and a global leader in providing innovative environmental solutions, today announced the signing of two new contracts in Slovakia.

Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June
globenewswire.com
2025-05-14 09:31:00Preclinical studies achieved therapeutically relevant gene editing levels of the HBG1/2 promoter & favorable biodistribution profile in non-human primates using a clinically validated editing strategy Data reinforces continued development as a potentially transformative, in vivo approach to treating sickle cell disease and beta thalassemia CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced that new data from a study in non-human primates (NHPs) has been accepted for a poster presentation at the European Hematology Association (EHA) 2025 Congress being held June 12-15, 2025, in Milan, Italy.

Harsco Environmental Opens First SteelPhalt™ Plant Outside the UK
globenewswire.com
2025-03-13 08:00:00Located in Murga, Basque Country, Spain, the new plant will offer environmental asphalt solutions to the region Steel Phalt ™ offers a true circular economy route for byproducts of the steel industry, offering high-quality asphalt without the use of natural aggregates ROTHERHAM, United Kingdom, March 13, 2025 (GLOBE NEWSWIRE) -- Harsco Environmental, a division of Enviri Corporation (NYSE: NVRI) and renowned global market leader in delivering innovative environmental solutions, today announced the opening of a new, state-of-the-art SteelPhalt plant in Murga, Basque Country, Spain. The plant is slated to host a grand opening event on March 19, 2025.

Harsco Environmental Secures Contract with İzmir Demir Çelik Sanayi A.Ş. (İDÇ)
globenewswire.com
2025-02-18 08:00:00PHILADELPHIA, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Harsco Environmental, a division of Enviri Corporation (NYSE: NVRI), today announced the signing of a contract with İzmir Demir Çelik Sanayi A.Ş. (İDÇ) in İzmir, Turkey.

Orchard Therapeutics Appoints Robin Kenselaar to Chief Commercial Officer and Announces Multiple Business Updates Pertaining to its Approved HSC Gene Therapy for MLD
globenewswire.com
2025-02-12 07:00:00First U.S. patients being treated with Lenmeldy™ (atidarsagene autotemcel) in a commercial setting; other launch efforts progressing well following Food and Drug Administration approval last year

Orchard Therapeutics Announces Multiple Data Presentations and Receives 2025 New Treatment Award at the 21st Annual WORLDSymposium™
globenewswire.com
2025-02-03 08:45:00Featured data showcase the transformative potential of HSC gene therapy to enable cross-correction and restore enzymatic function in a variety of tissues and organs, including the CNS Featured data showcase the transformative potential of HSC gene therapy to enable cross-correction and restore enzymatic function in a variety of tissues and organs, including the CNS

BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)
prnewswire.com
2024-05-30 07:00:00- Investigator-initiated study includes leading researchers in SCD gene therapy clinical development from St. Jude Children's Research Hospital, Inc. and two other clinical sites - - New trial to expand ongoing clinical research of motixafortide for mobilization of HSCs in patients with SCD - TEL AVIV, Israel , May 30, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced a multi-center Phase 1 clinical trial sponsored by St. Jude Children's Research Hospital, Inc. to evaluate motixafortide for the mobilization of CD34+ hematopoietic stem cells (HSCs) used in the development of gene therapies for patients with sickle cell disease (SCD).

Panagora Asset Management Inc. Invests $3.12 Million in Enviri Co. (NYSE:NVRI)
https://www.defenseworld.net
2024-05-20 07:24:44Panagora Asset Management Inc. bought a new stake in Enviri Co. (NYSE:NVRI – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 347,073 shares of the company’s stock, valued at approximately $3,124,000. Panagora Asset Management Inc. owned 0.43% of Enviri as of its most recent filing with the Securities and Exchange Commission. Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Diversified Trust Co bought a new position in Enviri in the fourth quarter valued at approximately $104,000. Brookstone Capital Management bought a new position in Enviri during the fourth quarter worth about $144,000. Legato Capital Management LLC acquired a new position in shares of Enviri during the 4th quarter worth about $1,212,000. D.B. Root & Company LLC bought a new stake in shares of Enviri in the 4th quarter valued at about $477,000. Finally, State of Alaska Department of Revenue bought a new position in Enviri during the 4th quarter worth approximately $442,000. 93.43% of the stock is owned by institutional investors. Insider Activity In related news, CEO F Nicholas Grasberger III bought 25,000 shares of the stock in a transaction that occurred on Monday, May 6th. The shares were acquired at an average price of $7.59 per share, with a total value of $189,750.00. Following the completion of the transaction, the chief executive officer now owns 837,901 shares in the company, valued at $6,359,668.59. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 1.70% of the company’s stock. Enviri Stock Performance Shares of NYSE NVRI opened at $8.24 on Monday. The firm has a 50 day moving average price of $8.26 and a 200 day moving average price of $7.94. The company has a debt-to-equity ratio of 2.65, a quick ratio of 1.03 and a current ratio of 1.36. Enviri Co. has a 52-week low of $5.64 and a 52-week high of $10.01. Enviri (NYSE:NVRI – Get Free Report) last released its quarterly earnings data on Thursday, May 2nd. The company reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.06. Enviri had a negative net margin of 4.35% and a negative return on equity of 0.99%. The business had revenue of $600.00 million during the quarter, compared to analysts’ expectations of $509.77 million. During the same quarter in the prior year, the company earned ($0.11) EPS. The firm’s quarterly revenue was up 7.0% on a year-over-year basis. On average, sell-side analysts forecast that Enviri Co. will post 0.01 EPS for the current year. About Enviri (Free Report) Enviri Corporation provides environmental solutions for industrial and specialty waste streams in the United States and internationally. The company operates through two segments: Harsco Environmental and Clean Earth. The Harsco Environmental segment offers on-site services under long-term contracts for material logistics, product quality improvement, and resource recovery for iron, steel, and metals manufacturing; manufactures and sells industrial abrasives, roofing granules, aluminum dross, and scrap processing systems; and meltshop and furnace services, such as under-vessel cleaning, removal of ladle slag, and general melt shop debris. See Also Five stocks we like better than Enviri Overbought Stocks Explained: Should You Trade Them? Canada Goose Flies Higher Driven By DTC Growth Best Aerospace Stocks Investing CVS Health Stock Has a Silver Lining Called Value What Are Dividend Contenders? Investing in Dividend Contenders Magnificent 7 Still Magnificent as the Halfway Mark Approaches? Want to see what other hedge funds are holding NVRI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enviri Co. (NYSE:NVRI – Free Report).

Harsco changes name to Enviri, to trade on ticker ‘NVRI'
marketwatch.com
2023-06-05 07:16:00Harsco Corp. HSC, +6.26% said Monday it has changed its name to Enviri Corp., effective immediately. Enviri Corp. will begin trading under the NYSE ticker “NVRI” on June 19.

Are Business Services Stocks Lagging Crawford & Company (CRD.A) This Year?
zacks.com
2023-05-31 10:45:25Here is how Crawford (CRD.A) and Harsco (HSC) have performed compared to their sector so far this year.

Despite Fast-paced Momentum, Harsco (HSC) Is Still a Bargain Stock
zacks.com
2023-05-30 09:55:10If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Harsco (HSC) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Does Harsco (HSC) Have the Potential to Rally 25.78% as Wall Street Analysts Expect?
zacks.com
2023-05-29 11:05:14The mean of analysts' price targets for Harsco (HSC) points to a 25.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Harsco Corporation: Investing In A Greener Future
seekingalpha.com
2023-05-17 15:33:48HSC's revenue growth should continue to benefit from higher price realization and healthy demand across both its businesses. Margins should benefit from pricing actions and productivity improvements.

Harsco Corporation (HSC) Q1 2023 Earnings Call Transcript
seekingalpha.com
2023-05-07 01:08:13Harsco Corporation (NYSE:HSC ) Q1 2023 Earnings Conference Call May 3, 2023 10:00 AM ET Company Participants David Martin - VP of IR Nick Grasberger - Chairman and CEO Pete Minan - SVP and CFO Conference Call Participants Larry Solow - CJS Securities Rob Brown - Lake Street Capital Markets Brian Butler - Stifel Operator Good morning. My name is Sarah, and I will be your conference facilitator.

Harsco (HSC) Reports Q1 Loss, Tops Revenue Estimates
zacks.com
2023-05-03 09:55:09Harsco (HSC) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.01 per share a year ago.

Harsco Corporation Announces Timing of First Quarter 2023 Results and Conference Call
globenewswire.com
2023-04-13 08:00:00PHILADELPHIA, April 13, 2023 (GLOBE NEWSWIRE) -- Harsco Corporation (NYSE: HSC) today announced that it will issue its first quarter 2023 earnings results on Wednesday, May 3, 2023 prior to NYSE market open. The Company will also host its quarterly conference call and webcast that morning beginning at 10:00 a.m. ET.

Harsco Environmental Expands Presence in Central Europe With Two New Contracts in Slovakia
globenewswire.com
2025-09-18 08:00:00LONDON, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Harsco Environmental, a division of Enviri Corporation (NYSE: NVRI), and a global leader in providing innovative environmental solutions, today announced the signing of two new contracts in Slovakia.

Editas Medicine to Present in vivo HSC Delivery, Editing, and Biodistribution Data at the European Hematology Association 2025 Congress in June
globenewswire.com
2025-05-14 09:31:00Preclinical studies achieved therapeutically relevant gene editing levels of the HBG1/2 promoter & favorable biodistribution profile in non-human primates using a clinically validated editing strategy Data reinforces continued development as a potentially transformative, in vivo approach to treating sickle cell disease and beta thalassemia CAMBRIDGE, Mass., May 14, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today announced that new data from a study in non-human primates (NHPs) has been accepted for a poster presentation at the European Hematology Association (EHA) 2025 Congress being held June 12-15, 2025, in Milan, Italy.

Harsco Environmental Opens First SteelPhalt™ Plant Outside the UK
globenewswire.com
2025-03-13 08:00:00Located in Murga, Basque Country, Spain, the new plant will offer environmental asphalt solutions to the region Steel Phalt ™ offers a true circular economy route for byproducts of the steel industry, offering high-quality asphalt without the use of natural aggregates ROTHERHAM, United Kingdom, March 13, 2025 (GLOBE NEWSWIRE) -- Harsco Environmental, a division of Enviri Corporation (NYSE: NVRI) and renowned global market leader in delivering innovative environmental solutions, today announced the opening of a new, state-of-the-art SteelPhalt plant in Murga, Basque Country, Spain. The plant is slated to host a grand opening event on March 19, 2025.

Harsco Environmental Secures Contract with İzmir Demir Çelik Sanayi A.Ş. (İDÇ)
globenewswire.com
2025-02-18 08:00:00PHILADELPHIA, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Harsco Environmental, a division of Enviri Corporation (NYSE: NVRI), today announced the signing of a contract with İzmir Demir Çelik Sanayi A.Ş. (İDÇ) in İzmir, Turkey.

Orchard Therapeutics Appoints Robin Kenselaar to Chief Commercial Officer and Announces Multiple Business Updates Pertaining to its Approved HSC Gene Therapy for MLD
globenewswire.com
2025-02-12 07:00:00First U.S. patients being treated with Lenmeldy™ (atidarsagene autotemcel) in a commercial setting; other launch efforts progressing well following Food and Drug Administration approval last year

Orchard Therapeutics Announces Multiple Data Presentations and Receives 2025 New Treatment Award at the 21st Annual WORLDSymposium™
globenewswire.com
2025-02-03 08:45:00Featured data showcase the transformative potential of HSC gene therapy to enable cross-correction and restore enzymatic function in a variety of tissues and organs, including the CNS Featured data showcase the transformative potential of HSC gene therapy to enable cross-correction and restore enzymatic function in a variety of tissues and organs, including the CNS

BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD)
prnewswire.com
2024-05-30 07:00:00- Investigator-initiated study includes leading researchers in SCD gene therapy clinical development from St. Jude Children's Research Hospital, Inc. and two other clinical sites - - New trial to expand ongoing clinical research of motixafortide for mobilization of HSCs in patients with SCD - TEL AVIV, Israel , May 30, 2024 /PRNewswire/ -- BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a commercial stage biopharmaceutical company pursuing life-changing therapies in oncology and rare diseases, today announced a multi-center Phase 1 clinical trial sponsored by St. Jude Children's Research Hospital, Inc. to evaluate motixafortide for the mobilization of CD34+ hematopoietic stem cells (HSCs) used in the development of gene therapies for patients with sickle cell disease (SCD).

Panagora Asset Management Inc. Invests $3.12 Million in Enviri Co. (NYSE:NVRI)
https://www.defenseworld.net
2024-05-20 07:24:44Panagora Asset Management Inc. bought a new stake in Enviri Co. (NYSE:NVRI – Free Report) in the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm bought 347,073 shares of the company’s stock, valued at approximately $3,124,000. Panagora Asset Management Inc. owned 0.43% of Enviri as of its most recent filing with the Securities and Exchange Commission. Other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Diversified Trust Co bought a new position in Enviri in the fourth quarter valued at approximately $104,000. Brookstone Capital Management bought a new position in Enviri during the fourth quarter worth about $144,000. Legato Capital Management LLC acquired a new position in shares of Enviri during the 4th quarter worth about $1,212,000. D.B. Root & Company LLC bought a new stake in shares of Enviri in the 4th quarter valued at about $477,000. Finally, State of Alaska Department of Revenue bought a new position in Enviri during the 4th quarter worth approximately $442,000. 93.43% of the stock is owned by institutional investors. Insider Activity In related news, CEO F Nicholas Grasberger III bought 25,000 shares of the stock in a transaction that occurred on Monday, May 6th. The shares were acquired at an average price of $7.59 per share, with a total value of $189,750.00. Following the completion of the transaction, the chief executive officer now owns 837,901 shares in the company, valued at $6,359,668.59. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 1.70% of the company’s stock. Enviri Stock Performance Shares of NYSE NVRI opened at $8.24 on Monday. The firm has a 50 day moving average price of $8.26 and a 200 day moving average price of $7.94. The company has a debt-to-equity ratio of 2.65, a quick ratio of 1.03 and a current ratio of 1.36. Enviri Co. has a 52-week low of $5.64 and a 52-week high of $10.01. Enviri (NYSE:NVRI – Get Free Report) last released its quarterly earnings data on Thursday, May 2nd. The company reported ($0.03) EPS for the quarter, beating analysts’ consensus estimates of ($0.09) by $0.06. Enviri had a negative net margin of 4.35% and a negative return on equity of 0.99%. The business had revenue of $600.00 million during the quarter, compared to analysts’ expectations of $509.77 million. During the same quarter in the prior year, the company earned ($0.11) EPS. The firm’s quarterly revenue was up 7.0% on a year-over-year basis. On average, sell-side analysts forecast that Enviri Co. will post 0.01 EPS for the current year. About Enviri (Free Report) Enviri Corporation provides environmental solutions for industrial and specialty waste streams in the United States and internationally. The company operates through two segments: Harsco Environmental and Clean Earth. The Harsco Environmental segment offers on-site services under long-term contracts for material logistics, product quality improvement, and resource recovery for iron, steel, and metals manufacturing; manufactures and sells industrial abrasives, roofing granules, aluminum dross, and scrap processing systems; and meltshop and furnace services, such as under-vessel cleaning, removal of ladle slag, and general melt shop debris. See Also Five stocks we like better than Enviri Overbought Stocks Explained: Should You Trade Them? Canada Goose Flies Higher Driven By DTC Growth Best Aerospace Stocks Investing CVS Health Stock Has a Silver Lining Called Value What Are Dividend Contenders? Investing in Dividend Contenders Magnificent 7 Still Magnificent as the Halfway Mark Approaches? Want to see what other hedge funds are holding NVRI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Enviri Co. (NYSE:NVRI – Free Report).

Harsco changes name to Enviri, to trade on ticker ‘NVRI'
marketwatch.com
2023-06-05 07:16:00Harsco Corp. HSC, +6.26% said Monday it has changed its name to Enviri Corp., effective immediately. Enviri Corp. will begin trading under the NYSE ticker “NVRI” on June 19.

Are Business Services Stocks Lagging Crawford & Company (CRD.A) This Year?
zacks.com
2023-05-31 10:45:25Here is how Crawford (CRD.A) and Harsco (HSC) have performed compared to their sector so far this year.

Despite Fast-paced Momentum, Harsco (HSC) Is Still a Bargain Stock
zacks.com
2023-05-30 09:55:10If you are looking for stocks that have gained strong momentum recently but are still trading at reasonable prices, Harsco (HSC) could be a great choice. It is one of the several stocks that passed through our 'Fast-Paced Momentum at a Bargain' screen.

Does Harsco (HSC) Have the Potential to Rally 25.78% as Wall Street Analysts Expect?
zacks.com
2023-05-29 11:05:14The mean of analysts' price targets for Harsco (HSC) points to a 25.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Harsco Corporation: Investing In A Greener Future
seekingalpha.com
2023-05-17 15:33:48HSC's revenue growth should continue to benefit from higher price realization and healthy demand across both its businesses. Margins should benefit from pricing actions and productivity improvements.

Harsco Corporation (HSC) Q1 2023 Earnings Call Transcript
seekingalpha.com
2023-05-07 01:08:13Harsco Corporation (NYSE:HSC ) Q1 2023 Earnings Conference Call May 3, 2023 10:00 AM ET Company Participants David Martin - VP of IR Nick Grasberger - Chairman and CEO Pete Minan - SVP and CFO Conference Call Participants Larry Solow - CJS Securities Rob Brown - Lake Street Capital Markets Brian Butler - Stifel Operator Good morning. My name is Sarah, and I will be your conference facilitator.

Harsco (HSC) Reports Q1 Loss, Tops Revenue Estimates
zacks.com
2023-05-03 09:55:09Harsco (HSC) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to loss of $0.01 per share a year ago.

Harsco Corporation Announces Timing of First Quarter 2023 Results and Conference Call
globenewswire.com
2023-04-13 08:00:00PHILADELPHIA, April 13, 2023 (GLOBE NEWSWIRE) -- Harsco Corporation (NYSE: HSC) today announced that it will issue its first quarter 2023 earnings results on Wednesday, May 3, 2023 prior to NYSE market open. The Company will also host its quarterly conference call and webcast that morning beginning at 10:00 a.m. ET.